Patents by Inventor Andreas Evers

Andreas Evers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS
    Publication number: 20180155407
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Katrin LORENZ, Dieter KADEREIT, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS
    Publication number: 20180155406
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Dieter KADEREIT, Katrin LORENZ, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID
    Publication number: 20180154005
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Martin BOSSART, Andreas EVERS, Peyman SAKHAII, Pradeep K. DHAL, Paul KONOWICZ, James E. STEFANO
  • Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
    Patent number: 9982029
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Bernd Henkel
  • Exendin-4 derivatives as selective glucagon receptor agonists
    Patent number: 9932381
    Abstract: The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 3, 2018
    Assignee: Sanofi
    Inventors: Torsten Haack, Siegfried Stengelin, Andreas Evers, Michael Wagner, Bernd Henkel
  • Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
    Patent number: 9834527
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 5, 2017
    Assignee: SANOFI
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
    Patent number: 9789165
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 17, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
    Patent number: 9775904
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 3, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
  • Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
    Patent number: 9771406
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 26, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Katrin Lorenz
  • Dual GLP-1/glucagon receptor agonists derived from exendin-4
    Patent number: 9758561
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • Non-acylated exendin-4 peptide analogues
    Patent number: 9750788
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Dual GLP-1/GIP receptor agonists
    Patent number: 9751926
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
    Patent number: 9745360
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 29, 2017
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
  • FUNCTIONALIZED EXENDIN-4 DERIVATIVES
    Publication number: 20170216406
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
  • Dual GLP-1/glucagon receptor agonists
    Patent number: 9694053
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 4, 2017
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9688645
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 27, 2017
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Functionalized exendin-4 derivatives
    Patent number: 9670261
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: June 6, 2017
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
  • EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
    Publication number: 20170022260
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: January 26, 2017
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Exendin-4 Derivatives as Selective Peptidic Dual GLP-1/Glucagon Receptor Agonists
    Publication number: 20170008944
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Katrin LORENZ, Dieter KADEREIT, Michael WAGNER, Bernd HENKEL
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20160251324
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: March 1, 2016
    Publication date: September 1, 2016
    Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER